Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: CNS Pharmaceuticals Inc. CNSP

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients

IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancersCompany holds the exclusive worldwide license for Berubicin, the first anthracycline … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright BioConnect 2021 Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO, John Climaco, will present at the virtual H.C. Wainwright … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

CNS Pharmaceuticals (NASDAQ: CNSP) Conducts Public Offering Funding Effort, Appears in Syndicated Broadcast on Brain Cancer Drug Advances

Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancersCNS’s Phase 2 trials are scheduled … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

Hour of Truth Approaching in CNS Pharmaceuticals (NASDAQ: CNSP) Testing of Drug Candidate Against Deadly Brain Cancer

A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next yearThe drug, Berubicin, is being developed by … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with Clinical Trials in 2021 after Receiving FDA Approval for IND for Berubicin

The company is scheduled to conduct three clinical trials in 2021 for Berubicin – two Phase II and the first-ever Phase I in pediatric patientsFDA modified the trial design to designate overall survival as the trial’s primary endpointThe market for … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosts Conference Call to Discuss IND Approval, Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference call to discuss its recently … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment